Today's Breaking News
- Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease
- OncoSec Medical Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial
- Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013
Latest R&D and Business News
- Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
- Teva Strengthens Respiratory Franchise with Acquisition of MicroDose Therapeutx
- Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma
- Vaxart’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans
- Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
- Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
- NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
- Amarantus Reports Positive Results on MANF Neuroprotective Properties Demonstrated in Preclinical Study in China
- Aurigene and Debiopharm Group™ Report Nomination of Development Candidate Debio 0617B in Oncology
- Celltrion files for approval of CT-P6, breast cancer mAb biosimilar, in Korea
- RemsimaTM extended clinical trial study was disclosed in EULAR 2013
- Karolinska Development AB (publ): Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosis